Important Legal Notice for Baxter International Investors
NEW YORK — Levi & Korsinsky, LLP is alerting shareholders of Baxter International, Inc. about a class action lawsuit concerning significant concerns regarding the company's financial practices. With the growth of market confidence, it is crucial for investors to stay informed about potential legal issues that may affect their investments.
Class Action Overview
The current class action lawsuit aims to recover losses on behalf of shareholders of Baxter International, Inc. This litigation arises from claims that the company's business practices led to substantial losses for investors. Specifically, allegations relate to a failure to disclose critical information regarding product safety and efficacy that may have jeopardized shareholder interests.
Allegations Against Baxter International
The lawsuit states that from February 23, 2022, to July 30, 2025, Baxter International, Inc. faced numerous complaints regarding its products. Key points include:
- The Novum LVP product, which encountered significant operational defects causing malfunctions, ultimately posing risks to patient safety.
- Numerous reports were made regarding severe injuries and fatalities resulting from these product failures.
- The company’s attempts to address the concerns through alerts were deemed inadequate, indicating deeper issues in product design.
- Due to these shortcomings, there was a growing risk of Baxter being required to withdraw existing devices and halt future sales.
- These events led to misleading assertions about product safety and market prospects.
What Investors Should Do
Shareholders who incurred losses during the specified period should be aware they have a deadline to act. Investors have the opportunity to file requests to be appointed as lead plaintiffs until mid-December. Engaging in the process may provide avenues for recovery even if one does not serve as a lead plaintiff.
Cost-Free Participation
It is important for affected shareholders to note that participation in this class action incurs no costs or fees. The firm representing the investors operates on the principle that class members may be entitled to compensation without out-of-pocket expenses. Therefore, the legal process presents no financial risk to class members and encourages all affected parties to participate.
Why Choose Levi & Korsinsky?
Levi & Korsinsky brings over two decades of experience in securities litigation, having secured significant recoveries for investors. Known for their dedication and expertise in managing complex legal cases, they stand out in the industry. Their team consists of over 70 professionals devoted to serving clientele, highlighting their dedication to achieving favorable outcomes. Levi & Korsinsky has achieved recognition in securities litigation, placing them among elite law firms within the industry.
Contact Information
Investors seeking further information are encouraged to reach out to Levi & Korsinsky, LLP:
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Frequently Asked Questions
What is the nature of the lawsuit involving Baxter International?
This class action lawsuit addresses allegations related to the company’s failure to disclose critical safety issues in its product line that affected shareholders.
How does a shareholder become a lead plaintiff in this case?
Shareholders can file requests to be appointed as lead plaintiffs by the court before an established deadline.
What costs are associated with participating in the class action?
There are no costs to participate; compensation is available without any out-of-pocket expenses for class members.
What should I do if I experienced losses due to Baxter International?
If you experienced losses during the relevant period, you should consider filling out the necessary information to join the class action lawsuit.
Why is Levi & Korsinsky reputable in securities litigation?
The firm has a long history of successful claims and a strong commitment to protecting shareholders’ rights, making them a trusted choice for legal representation.
